Detail page

Knowledge Web

Person

Thomas Karn (1964-)

Biologe

Name	Thomas Karn
Time	1964- (Date of birth and death)
Place	Frankfurt am Main (Geburtsort) Deutschland
Academic degree	Dr. phil. nat (Fachbereich Biochemie, Pharmazie und Lebensmittelchemie der Univ. Frankfurt (Main)) (1997)
Profession	Biologe (characteristic profession)
Variant	T. Karn
Further information	Habil. Fach Experimentelle Frauenheilkunde und Geburtshilfe am Fachbereich Medizin der Univ. Frankfurt (Main)
Record type	Person
GND-Identifier	118155822
Record ID	118155822
Involved in show all Prognostic impact of metabolic syndrome in patients with primary endometrial cancer: a retrospective bicentric study Breast cancers with high proliferation and low ER-related signalling have poor prognosis and unique molecular features with implications for therapy Molecular differences between younger versus older ER-positive and HER2-negative breast cancers Correction to: TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer Correction to: TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer Correction to: TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapy Clinical relevance of collagen protein degradation markers c3m and c4m in the serum of breast cancer patients treated with neoadjuvant therapy in the geparquinto trial Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapy Identification and validation of a novel biologics target in triple negative breast cancer BRCA1-like profile is not significantly associated with survival benefit of non-myeloablative intensified chemotherapy in the GAIN randomized controlled trial Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers Homogeneous datasets of triple negative breast cancers enable the identification of novel prognostic and predictive signatures Subtyp-spezifische Analysen des Mammakarzinoms in der molekularen Gynäkologie zur Entwicklung einer personalisierten Therapie Brustkrebs: Auf dem Weg zu einer personalisierten Therapie : molekulare Subtypen und "Wirtsfaktoren" entscheiden über Prognose und Therapie-Erfolg T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers Detektion und Charakterisierung von Proteinkinasen

Please note

The beta version does not yet contain all functions and information of the DNB portal catalogue. If you are missing information or want to order a medium, please visit the page in the DNB portal catalogue via the following link:

Katalog der Deutschen Nationalbibliothek

Thomas Karn (1964-)

Prognostic impact of metabolic syndrome in patients with primary endometrial cancer: a retrospective bicentric study

Breast cancers with high proliferation and low ER-related signalling have poor prognosis and unique molecular features with implications for therapy

Molecular differences between younger versus older ER-positive and HER2-negative breast cancers

Correction to: TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer

TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer

Correction to: TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer

Correction to: TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer

TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer

TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer

TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer

Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapy

Clinical relevance of collagen protein degradation markers c3m and c4m in the serum of breast cancer patients treated with neoadjuvant therapy in the geparquinto trial

Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapy

Identification and validation of a novel biologics target in triple negative breast cancer

BRCA1-like profile is not significantly associated with survival benefit of non-myeloablative intensified chemotherapy in the GAIN randomized controlled trial

Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers

Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers

Homogeneous datasets of triple negative breast cancers enable the identification of novel prognostic and predictive signatures

Subtyp-spezifische Analysen des Mammakarzinoms in der molekularen Gynäkologie zur Entwicklung einer personalisierten Therapie

Brustkrebs: Auf dem Weg zu einer personalisierten Therapie : molekulare Subtypen und "Wirtsfaktoren" entscheiden über Prognose und Therapie-Erfolg

T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers

T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers

Detektion und Charakterisierung von Proteinkinasen